Other Targets

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC12438	G6PD activator AG1 Featured	G6PD activator AG1 (AG1) is a specific, small molecule that increases the activity of the wild-type, Canton mutant (R459L, EC50=3 uM) and several other common G6PD mutants; displays no effect on the dimerization or activity of several other NAD- or NADP+-dependent dimeric or tetrameric enzymes, including 6PGD, GAPDH, ALDH2, and ALDH3A1; attenuates ROS-induced pericardial edema in a G6PD-dependent manner in zebrafish, reduces hemolysis of human erythrocytes
DC21035	G907	G907 is a potent, selective small-molecule antagonist of ATP-binding cassette (ABC) transporter MsbA with IC50 of 18 nM.
DC21036	E-72	G9a inhibitor E72 (E-72) is a potent inhibitor of histone H3K9 methyltransferases G9a and G9a-like protein (GLP) with Kd of 136 nM and 164 nM, shows selectivity over the related H3K9 methyltransferase Suv39H2.
DC9129	Gabexate mesylate	Gabexate Mesylate is a Factor X inhibitor.
DCAPI1037	Gadodiamide (Omniscan) Featured	Gadodiamide is a gadolinium-based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. Target: OthersGadodiamide(Omniscan) is a gadolinium-based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. Gadodiamide is a contrast medium for cranial and spinal magnetic resonance imaging (MRI) and for general MRI of the body after intravenous administration. The product provides contrast enhancement and facilitates visualisation of abnormal structures or lesions in various parts of the body including the central nervous system (CNS). A recent review takes the question of toxicity caused by loss of gadolinium from the complex. "The challenge for nephrologists includes (a) evidence of transmetallation, such as gadolinium deposits in bone, increased urinary zinc excretion, iron-transferrin dissociation or 'spurious hypocalcemia' in exposed people"。
DC11053	GAK inhibitor 49 Featured	GAK inhibitor 49 is a potent, selective, ATP-competitive inhibitor of cyclin G-associated kinase (GAK, cell IC50=56 nM) with favourable NAK family selectivity (AAK1, STK16, BMP2K).
DC12228	Galactose 1-phosphate	Galactose 1-phosphate is an intermediate in the galactose metabolism and nucleotide sugars.
DC12305	Galactose 1-phosphate Potassium salt	Galactose 1-phosphate Potassium salt is is an intermediate in the galactose metabolism and nucleotide sugars
DC21038	Galvestine-1	Galvestine-1 is a small molecule MGDG (monogalactosyldiacylglycerol) synthase inhibitor with IC50 of 10 uM by competing with diacylglycerol binding.
DC12090	Gamitrinib TPP	Gamitrinib TPP is a GA mitochondrial matrix inhibitor.
DC9640	gamma-secretase modulator 3	gamma-secretase modulator 3 is a gamma-secretase modulator.
DC21197	Ganaplacide Featured	Ganaplacide (KAF156, GNF-156) is a novel antimalarial clinical candidate that shows blood schizonticidal activity with IC50 of 6-17.4 nM against P falciparum drug-sensitive and drug-resistant strains.
DCAPI1357	Ganciclovir	Ganciclovir
DC8877	Ganirelix Featured	Ganirelix is a man-made form of a protein that reduces the amount of certain hormones in the body, including estrogen.
DC7129	GANT61(NSC 136476) Featured	GANT 61(NSC 136476) is a small molecule inhibitor of Gli1 and Gli2.
DC20388	GAPDS Featured	GAPDS is a small molecule that targets the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
DC23398	Garcinol	Garcinol (Camboginol) is a potent, natural inhibitor of histone acetyltransferases (HATs) p300 (IC50=7 uM) and PCAF (IC50=5 uM) both in vitro and in vivo.
DC22098	GB1107	GB1107 (GB-1107, GB 1107) is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with Kd of 37 nM (human Galectin-3).
DC21040	GB-83	GB-83 is a selective, reversible PAR2 (Protease-activated receptor 2) antagonist with IC50 of 2 uM.
DC12671	Gboxin Featured	Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma.
DC10474	GBT-440(Voxelotor) Featured	GBT-440(Voxelotor) is a novel small molecule hemoglobin modifier which increases hemoglobin oxygen affinity.
DC10896	GCN2-IN-1 Featured	GCN2-IN-1 is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with IC50s of <0.3 μM in the enzyme and cell assay.
DC7416	Taselisib（GDC-0032） Featured	GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with IC50 of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.
DC3109	Ipatasertib (GDC-0068) Featured	GDC-0068 is a highly selective pan-Akt inhibitor targeting Akt1, Akt2 and Akt3 with IC50 of 5 nM, 18 nM and 8 nM, respectively.
DC8597	Gdc-0152 Featured	GDC-0152 is a potent inhibitor of IAPs; binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with K(i) values of 28, 14, 17, and 43 nM, respectively.
DC8216	GDC-0349	GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM; >700-fold selectivity over PI3Kα and other 266 kinases.
DC8519	GDC046 Featured	GDC046 is a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile.
DC8000	GDC-0623 Featured	GDC-0623 is a potent, ATP-uncompetitive inhibitors of MEK1(Ki=0.13 nM, +ATP).
DC23714	GDC-0927 R-form	GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer..
DC23717	GDC-0927	GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer..

Other Targets

Customized Consultation X

Your information is safe with us. * Required Fields.